These trials have addressed breast cancer, colon cancer, lung cancer, ovarian cancer, pancreatic cancer, prostate cancer, and urothelial cancer, utilizing various mTOR inhibitors such as rapamycin, everolimus, metformin, and sirolimus. Here, MTOR is linked to pancreatic neoplasm.